Common use

Tivicay (dolutegravir) is a potent integrase strand transfer inhibitor (INSTI) prescribed as part of combination antiretroviral therapy (ART) for adults, adolescents, and children with HIV-1 infection. Dolutegravir works by blocking the HIV integrase enzyme, which prevents the virus from inserting its genetic material into the DNA of healthy human immune cells. By halting this critical step in viral replication, Tivicay helps reduce HIV viral load to undetectable levels and allows the immune system to recover by increasing CD4+ T-cell counts. Tivicay is recommended as a first-line treatment option by major HIV treatment guidelines due to its high efficacy, high genetic barrier to resistance, and favorable tolerability profile. Buy Tivicay online at dutypills.ovh for affordable HIV treatment with discreet, worldwide shipping.

Dosage and direction

Tivicay is taken orally, once or twice daily depending on your specific treatment regimen, HIV resistance profile, and co-administered medications. The standard dose for treatment-naive adults is 50 mg once daily. For patients taking certain enzyme-inducing drugs or with known integrase resistance mutations, the dose may be increased to 50 mg twice daily. Tablets should be swallowed whole with water, with or without food. Follow your doctor's dosage instructions precisely and take Tivicay at the same time each day to maintain consistent blood levels of the medication. Do not discontinue antiretroviral therapy without medical supervision, as this may lead to viral rebound and drug resistance.

Precautions

Before starting Tivicay, inform your doctor if you have liver disease (including hepatitis B or C co-infection), kidney problems, a history of mental health disorders including depression or suicidal ideation, or if you are pregnant, planning to become pregnant, or breastfeeding. Dolutegravir has been associated with neural tube defects when taken around the time of conception, so women of childbearing potential should discuss contraception options with their healthcare provider. Tivicay may cause weight gain, changes in body fat distribution, and elevations in blood sugar, cholesterol, or liver enzymes. Avoid taking magnesium- or aluminum-containing antacids, calcium supplements, or iron supplements within 2 hours before or 6 hours after your Tivicay dose, as they can significantly reduce drug absorption. Patients with hepatitis B co-infection should be monitored for hepatic flares upon discontinuation of dolutegravir.

Contraindications

Do not use Tivicay if you have a known allergy to dolutegravir or any component of the tablet formulation. Tivicay is strictly contraindicated in patients concurrently taking dofetilide, as dolutegravir increases dofetilide plasma concentrations, potentially leading to serious and life-threatening cardiac arrhythmias including QT prolongation and torsades de pointes.

Possible side effect

Common side effects of Tivicay include insomnia, headache, fatigue, nausea, diarrhea, and dizziness. Some patients may experience elevated creatine kinase levels or increased liver enzymes. Serious side effects requiring immediate medical attention include severe allergic reactions (rash, blisters, fever, swelling of the face, eyes, lips, or mouth, difficulty breathing), hepatotoxicity (yellowing of the skin or eyes, dark urine, pale stools), depression, anxiety, suicidal thoughts or behavior (particularly in patients with a pre-existing history of psychiatric illness), and immune reconstitution inflammatory syndrome (IRIS). Seek medical attention promptly if any severe or persistent symptoms develop.

Drug interaction

Tivicay may interact significantly with polyvalent cation-containing products (antacids, calcium, iron, and magnesium supplements), rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John's Wort, etravirine (without boosted protease inhibitors), metformin, and certain other HIV medications. Dolutegravir can increase metformin concentrations, so dose adjustment of metformin may be necessary. Strong CYP3A4 and UGT1A1 inducers may decrease dolutegravir levels, reducing its antiviral effectiveness. Always provide your healthcare provider with a complete list of all medicines, supplements, and herbal products you take to prevent potentially dangerous interactions.

Missed dose

If you miss a dose of Tivicay, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue your regular schedule. Do not take two doses at once to compensate. Consistent daily adherence is critical for maintaining viral suppression and preventing the development of drug-resistant HIV.

Overdose

Symptoms of dolutegravir overdose may include nausea, headache, dizziness, or more serious adverse reactions. There is no specific antidote for Tivicay overdose. Seek immediate medical attention or contact a poison control center if an overdose is suspected. Treatment is supportive and symptom-based, with monitoring of vital signs and clinical status.

Storage

Store Tivicay at controlled room temperature between 68°F and 77°F (20°C to 25°C), protected from moisture, heat, and direct light. Keep the medication in its original container with the cap tightly closed. Store out of the reach of children and pets.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.